RESEARCH

Serum Zinc and C-Reactive Protein Levels as Risk Factors for Mortality in Systemic Inflammatory Response Syndrome
(Kadar Zinc dan C-Reactive Protein Serum Sebagai Faktor Kebahayaan Kematian di Pasien Systemic Inflammatory Response Syndrome)

Dwi Retnoningrum, Banundari Rachmawati, Dian Widyaningrum .......................................................... 1–5

Correlations between Mean Platelet Volume and Immature Platelet Fraction to Hemoglobin A1c in Patients with Type 2 Diabetes Mellitus
(Kenasaban antara Mean Platelet Volume dan Immature Platelet Fraction terhadap Hemoglobin A1c di Pasien Diabetes Melitus Tipe 2)

Dian W Astuti, Sony Wibisono, Arifoel Hajat, Sidarti Soehita .................................................................. 6–11

Methicillin-Resistant Staphylococcus Aureus Colonization and Screening Method Effectiveness for Patients Admitted to the Intensive Care
(Kejadian dan Ketepatgunaan Penapisan Kolonisasi Methicillin-Resistant Staphylococcus aureus di Pasien Perawatan Intensif)

Andaru Dahesihdewi, Budi Mulyono, Iwan Dwiprahasto, Supra Wimbarti ................................................... 12–18

Correlation between Visceral Adipose Tissue-Derived Serpin with Fasting Blood Glucose Level in Obesity
(Hubungan Kadar Visceral Adipose Tissue-Derived Serpin Dengan Kadar Glukosa Darah Puasa Pada Kegemukan)

Novi Khila Firani, Agustin Iskandar, Anik Widijanti, Nonong Eriani .......................................................... 19–23

Serum Glial Fibrillary Acidic Protein Levels Profile in Patients with Severe Traumatic Brain Injury
(Profil Kadar Glial Fibrillary Acidic Protein Serum di Pasien Cedera Otak Berat)

Arief S. Hariyanto, Endang Retnowati, Agus Turchan .............................................................................. 24–28

Phylogenetic Profile of Escherichia coli Causing Bloodstream Infection and Its Clinical Aspect
(Profil Filogenetik Escherichia coli Penyebab Infeksi Aliran Darah dan Aspek Klinisnya)

Osman Sianipar, Widya Asmara, Iwan Dwiprahasto, Budi Mulyono ................................................................. 29–35

Comparison of Glycemic State in Patients with and without Hyperuricemia
(Perbedaan Status Glikemia pada Pasien dengan dan tanpa Hiperurisemia)

Corrie Abednego, Banundari Rachmawati, Muji Rahayu ........................................................................... 36–41

Analysis of Laboratory Parameters as Sepsis Markers in Neonatals with Hyperbilirubinemia
(Analisis Tolok Ukur Laboratorium Sebagai Petanda Sepsis di Neonatus dengan Hiperbilirubinemia)

Bachtiar Syamsir, Rachmawati Muhiiddin, Uleng Bahrun ........................................................................... 42–46

Correlation Percentage of S and G2/M with Percentage of Lymphoblasts in Pediatric Acute Lymphoblastic Leukemia
(Kenasaban Persentase S dan G2/M dengan Persentase Limfoblas di Pasien Leukemia Limfoblastik Akut Anak)

Erawati Armayani, Yetti Hernaningsih, Endang Retnowati, Suprapto Ma’at, I Dewa Gede Ugrasena . 47–52
Correlation of Blast Percentage to CD34 of Bone Marrow in All Pediatric Patients  
*(Kenasaban Persentase Blas Dengan CD34 di Sumsum Tulang pada Pasien LLA Anak)*

**Rahmi Rusanti, Yetti Hernaningisih, Endang Retnowati, Mia Ratwita Andarsini, Andy Cahyadi**  
53–58

Analysis of Decreased Glucose Level in Stored Samples Correlated to Serum Separation and Temperature Storage  
*(Analisis Penurunan Glukosa Dari Sampel Yang Disimpan Dalam Kaitannya Dengan Pemisahan Serum dan Suhu Penyimpanan)*

**Gustamin, Liong Boy Kurniawan, Ruland DN Pakasi**  
59–63

Diagnostic Concordance between Next Generation and High Sensitive Troponin-I in Angina Pectoris Patients  
*(Kesesuaian Diagnostik Troponin-I Next generation dan High sensitive di Pasien Angina Pectoris)*

**Erna R Tobing, Jusak Nugraha, Muhammad Amminuddin**  
64–69

Elevated Serum S100B Protein Level as a Parameter for Bad Outcome in Severe Traumatic Brain Injury Patients  
*(Peningkatan Kadar Serum Protein S100B Sebagai Tolok Kelaaran Buruk di Pasien Cederai Kepala Berat)*

**Ridha Dharmajaya, Dina Keumala Sari, Ratna Akbari Ganie**  
70–75

Analysis of Mean Platelet Volume As A Marker For Myocardial Infarction and Non-Myocardial Infarction in Acute Coronary Syndrome  
*(Analisis Mean Platelet Volume sebagai Pembeda Infark Miokard dan Non-Infark Miokard di Sindrom Koroner Akut)*

**Wandani Syahrir, Liong Boy Kurniawan, Darmawaty Rauf**  
76–80

Anti-Dengue IgG/IgM Ratio for Secondary Adult Dengue Infection in Surabaya  
*(Rasio IgG/IgM Anti Dengue untuk Infeksi Dengue Sekunder Dewasa di Surabaya)*

**Aryati, Purpa Wardhani, Ade Rochaeni, Jeine Stela Akualing, Usman Hadi**  
81–85

Analysis of Blood Urea Nitrogen/Creatinin Ratio to Predict the Gastrointestinal Bleeding Tract Site  
*(Analisis Rasio Blood Urea Nirogen/Kreatinin Untuk Meramalkan Lokasi Perdarahan pada Saluran Cerna)*

**Arfandhy Sanda, Mutmainnah, Ibrahim Abdul Samad**  
86–90

The Differences of Sodium, Potassium and Chloride Levels in STEMI and NSTEMI Patients  
*(Perbedaan Kadar Natrium, Kalium dan Klorida di Pasien STEMI dan NSTEMI)*

**Freddy Ciptono, Muji Rahayu**  
91–94

LITERATURE REVIEW

Macrophage Autophagy in Immune Response  
*(Otofagi Makrofag dalam Respons Imun)*

**Jusak Nugraha**  
95–101

CASE REPORT

Very Severe Hypertriglyceridemia in Suspected Familial Chylomicronemia Infant  
*(Hipertrigliseridemia Sangat Berat di Bayi Terduga Kausa Familial Chylomicronemia)*

**Fitry Hamka, Liong Boy Kurniawan, Suci Aprianti**  
102–107
DIAGNOSTIC CONCORDANCE BETWEEN NEXT-GENERATION AND HIGH SENSITIVE TROTONIN-I IN ANGINA PECTORIS PATIENTS

(Kesesuaian Diagnostik Troponin-I Next-generation dan High sensitive di Pasien Angina Pectoris)

Erna R Tobing¹, Jusak Nugraha¹, Muhammad Amminuddin²

ABSTRACT

Angina pectoris is a symptom of Acute Coronary Syndrome (ACS) leading to coronary heart disease, consisting of Unstable Angina (UA) and Acute Myocardial Infarction (AMI). Troponin I (TnI) level can help to establish the AMI diagnosis in angina pectoris patients. Some methods of TnI assay have been developed, such as high sensitive TnI (hsTnI) and next-generation TnI (ngTnI). The aim of this study was to analyze the diagnostic concordance between ngTnI using Fluorescent Energy Transfer Latex (FETL) method [Alere Triage MeterPro®] and hsTnI using Chemiluminescent Enzyme Immunoassay (CLEIA) method [Mitsubishi Pathfast] in angina pectoris patients. This was a cross-sectional study done in the Dr. Soetomo Hospital Surabaya in March-July 2016. The 82 patients with angina pectoris were examined for TnI level simultaneously with both methods. Forty-four percent of subjects were diagnosed as ACS and 56% were non-ACS. The concordance value between ngTnI and hsTnI results in ACS patients was 0.738 (p<0.01). The sensitivity and specificity of ngTnI to hsTnI with a cut off 0.02 ng/mL were 94% and 78%. Analysis between ngTnI and hsTnI with Spearman test revealed a correlation coefficient rho (ρ) = 0.826 (p<0.01). There was a diagnostic concordance between ngTnI and hsTnI in angina pectoris patients. Further research is needed for analyzing the prognostic value of TnI.

Key words: Troponin I, angina pectoris, ACS, FETL, CLEIA

¹ Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital Surabaya, Indonesia, Indonesia.  
E-mail: ernatobing@gmail.com  
² Department of Cardiology and Vascular Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital Surabaya, Indonesia
INTRODUCTION

Angina pectoris is the primary symptom of Acute Coronary Syndrome (ACS) leading to Coronary Heart Disease (CHD). Pathophysiology of ACS begins with the formation of atherosclerosis in the coronary arteries that provide vascularization to the heart muscle. The presence of atherosclerosis causes vasoconstriction and thrombus formation of coronary arteries which can disturb the myocardial perfusion. Ischemia and necrosis of the myocardial muscle causes chest pain, changes in the myocardial electricity and cardiac protein secretion. Acute coronary syndrome consists of Unstable Angina (UA) and Acute Myocardial Infarction (AMI), which includes Non-ST-segment Elevation Myocardial Infarction (NSTEMI) and ST-segment Elevation Myocardial Infarction (STEMI). These diseases can be found mostly in 40-60 years of age, more common in males than females. High rate of morbidity and mortality in ACS patients is due to AMI. Acute myocardial infarction is predicted to be the first common killer worldwide in 2020 which amounts to 36% of all deaths.

The importance of establishing the diagnosis of AMI in ACS patients is a challenge for clinicians to reduce the disability and mortality due to AMI in ACS patients. AMI is established when at least two of the three criteria are met, the following criteria, such as: specific chest pain (angina pectoris); changes in electrocardiography (ECG) pattern and an increase in cardiac biomarkers. Myocardial biomarker assays have an important role in diagnosing ACS especially in patients with nonspecific symptoms and ECG. TnI is the most recommended biomarker because of its better sensitivity and specificity among other biomarkers. Troponin I assay method has been developed to give rapid, accurate and precise results. Several methods of troponin I assay give some sort of parameters of troponin I based on the sensitivity like low sensitive, moderate/contemporary sensitive and high sensitive troponin I (hsTnI ). Assay method with hsTnI results can detect a very low elevated level of troponin I. One hs TnI assay method is ChemiLuminescent Enzyme ImmunoAssay method (CLEIA) examined by Mitsubishi PathFast and is used in the Emergency Department (ED), Dr. Soetomo Hospital, Surabaya. Hs TnI examination generally requires sophisticated equipment with advance electrical installations and laboratory facilities so this may not be available in a tertiary laboratory center.

The need of Troponin I examination for diagnosing AMI rapidly and accurately is also for tertiary health facilities that may not have adequate facilities to provide advanced instruments such as those in the Dr. Soetomo Hospital. Alternative methods for troponin I assay is the Fluorescent Energy Transfer Latex (FETL) method by Alere Triage MeterPro that produces troponin I level named as next-generation troponin I (ngTnI) by the company. Fluorescent Energy Transfer Latex method is said to be able to provide a quite sensitive result of troponin I with a smaller instrument, practical, portable and simpler electrical installation. The diagnostic performance of ngTnI parameter as a diagnostic instrument for the ACS stratification and diagnosing AMI is unknown. The gold standard for TnI examination is patients with AMI, while the reference method for TnI assay is still controversial. Assay methods that produce a hsTnI deemed good enough so that it can be used as a comparison method for ngTnI. The aim of this study was to analyze the diagnostic concordance between ngTnI and hsTnI using the above methods in angina pectoris patients.

METHODS

This study was observational analytical with cross-sectional design. The subjects were all patients who visited the Emergency Department of the Dr. Soetomo Hospital, Surabaya from March to July 2016, with complaints of persistent chest pain for > 20 minutes, felt through to the back or spreading to the shoulders, left side arms, neck, mandible or epigastrium, not localized, not associated with movement and position, not disappearing by resting, did not respond or minimally respond to the administration of drugs such as nitrates, could be accompanied by shortness of breath, cold sweat, nausea, or syncope and met the inclusion criteria. The inclusion criteria included age >=30 years, signed an informed consent and have a complete medical record. Patients with sepsis and chronic kidney disease were excluded. All study subjects underwent history taking, ECG, physical and laboratory examination.

Troponin I level was examined once in the Emergency Department using EDTA Venous blood sample with Alere Triage MeterPro® and Mitsubishi Pathfast®. Diagnosis of ACS was established by a cardiologist based on criteria of the World Health Organisation (WHO) minimally fulfilling 2 from 3 criteria such as: specific chest pain; electrocardiography (ECG) changes showing patterns such as ST elevation or Q wave; increasing myocardial biomarkers such as CKMB, Troponin I, Troponin T and myoglobin.
The level of the TnI was checked once when the patients were in the ED using Alere Triage MeterPro® and Mitsubishi PathFast®. Performance characteristics of the troponin I examination was shown in Table 1. Next-generation troponin I was the result of examining troponin I using Alere Triage MeterPro®. The assay method was FETL where an analyte in the sample will bind to fluorescently conjugated antibodies and flow in the test device by capillarity. The test device was inserted into the Triage MeterPro and the fluorescent signal was measured within 20 minutes. High sensitive troponin I was the result of examining troponin I using Mitsubishi PathFast®. The high sensitive assay used CLEIA method where the sample was inserted into a reagents cartridge and the analyte will bind the alkaline phosphatase conjugated antibodies that were bound to the magnetic particles. The immune complex formed will be separated from the unbound antibodies by the magnetic field. Chemiluminescence substrate was added and the alkaline phosphatase enzyme from the immune complex will degrade the substrate then produce luminescence light which will be detected by the Pathfast appliance and the result was converted to the level of the troponin I.

The results of an examination of the troponin I was also compared between diagnosis of AMI and non-AMI by a cardiologist. Diagnosis of AMI was established based on the criteria according to the World Health Organization (WHO) which met at least 2 of 3 the following criteria: specific chest pain; changes ECG pattern such as ST-segment elevation or Q waves; (3) Increasing cardiac biomarkers such as CKMB, Troponin I, Troponin T and myoglobin.

Statistical metrics were calculated by using SPSS 9.3. The diagnostic concordance was evaluated by Kappa Cohen test. Sensitivity and specificity were calculated at a clinical cutpoint defined as the 99th percentile of concentrations from the normal reference population. This value was 0.02 ng/mL for Triage TnI and PathFast, based on the manufacturer’s recommendations. The degree of analytical correlation was tested in samples with detectable troponin levels between the Triage and PathFast. The correlation was evaluated by using Spearman correlation statistics. Only subjects with measured values between the lower and upper limits for both assays in each comparison were included in correlation computations (Triage TnI: lower=0.01 ng/mL, upper=10 ng/mL; PathFast: lower=0.001 ng/mL, upper=50 ng/mL).

### RESULT & DISCUSSION

The total research samples from 82 subjects consisted of 62 (75.6%) males and 31 (24.4%) females aged 39-82 years with an average age of 57 (SD=10 year). The results of this study showed that 56% subjects were diagnosed as non-ACS and 44% were ACS consisting of STEMI 34% and NSTEMI 55%. ACS patients consisted of 86.11% males and 13.88% females. The value of diagnostic concordance (kappa) between TnI ng and TnI hs on suspected ACS patients was 0.738 (p<0.01) meaning that there was a good concordance between the results of the TnI ng and TnI hs. The obtained value of the diagnostic concordance in the ACS patients itself was perfect (kappa: 1,000), while in patients with non-

### Table 1. Assay performance characteristic

<table>
<thead>
<tr>
<th>LOD</th>
<th>Alere Triage (TnI ng)</th>
<th>PathFast (TnI hs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>0.02 (Limit of blank, 0.01 ng/mL)</td>
<td>0.008 ng/mL</td>
</tr>
<tr>
<td>LOQ</td>
<td>0.02 ng/mL</td>
<td>0.01 ng/mL</td>
</tr>
<tr>
<td>Reportable range</td>
<td>0.01-10 ng/mL</td>
<td>0.01 – 50 ng/mL</td>
</tr>
<tr>
<td>99th percentile</td>
<td>0.02 ng/mL</td>
<td>0.029 ng/mL</td>
</tr>
<tr>
<td>CV</td>
<td>16.7% at 0.06 ng/mL and 11% at 5 ng/mL</td>
<td>6.1% at 0.02 ng/mL and 3.9% at 2.51 ng/mL</td>
</tr>
<tr>
<td>CV at 99th percentile</td>
<td>&lt;20 %</td>
<td>5%</td>
</tr>
</tbody>
</table>

Abbreviations: N/A, Not Available; LOD, Level of Detection; LOQ, Level of Quantitation; CV, Coefficient Variation; TnI ng, Troponin I next-generation; TnI hs, Troponin I high sensitive
ACS there were still differences between the results of the next-generation and high sensitive troponin I. Table 2 showed all subject data results from the ngTnI against hsTnI. The sensitivity and specificity of next-generation TnI against the hs TnI was 94% and 78%, respectively. Table 3 showed the ngTnI and hsTnI data result distribution based on AMI and non-AMI patients. Correlation analysis between ngTnI level and hsTnI by Spearman test revealed a correlation coefficient rho (ρ) = 0.826 (p <0.01).

Non-AMI patients consisted of patients with UA and non-ACS. The positive troponin I results was found not only in patients with AMI, but also in patients with non-ACS including chronic heart failure, stable coronary disease, abnormal heart rhythm (atrial fibrillation, supraventricular tachycardia, bradycardia), cardiomyopathy, pericardial effusion post CABG, diabetes mellitus, HIV infection and chronic lung disease. Similar results were found in the study of Khan et al9 where troponin I was also found in patients with diagnosis of hypertrophic obstructive, post resuscitation measures of the heart, HIV, central nervous system disease, pulmonary disease, chronic heart failure and hormonal disorders.9 Troponin I secretion in non-ACS patients with diagnosis of cardiovascular disease was associated with the myocardial damage process. Myocardial necrosis was not only caused by myocardial infarction, but also other cardiovascular disease. The myocardial necrosis whatever the cause can elevate troponin I in the circulation.9 Mechanism that can explain the elevated troponin I in non-ACS patients with non-cardiovascular disease is the process of systemic organ failure in diseases including heart and also one theory that said that there was a non-specific component like acute phase protein which can bind to the capture antibodies.9 These theories associating troponin I elevation outside in AMI was still a speculation, while the true mechanism was not yet clear.

A study of Collison et al10 revealed that troponin I had a very high diagnostic sensitivity for AMI, while the specificity was varied between 46-98%.10 The specificity was affected by other conditions other than IMA. The study of Carlton et al11 revealed that the sensitivity of high sensitive TnI with a cut off 0.12 ng/mL was 99% and the negative predictive value was 99.5%, while the study of Neuman et al12 revealed that the sensitivity of high sensitive TnI with cut off 0.06 ng/mL was 99.8% and the positive predictive value was 82.8%.11,12 A study by Peacock et al13 revealed that the sensitivity and specificity of Alere Triage troponin I result was 79.3% and 91.1%; while the high sensitive TnI using Mitsubishi PathFast was 76.7% and 96.8%.13 Differences in results can be caused by the differences in the methods of examination, the value of the cut off used and differences in research methods such as sample size, sampling method, blood sampling time, etc. A study of Khan et al9 concluded that troponin I was not a specific cardiac biomarker for AMI, although elevation of troponin I level in non-ACS patients was usually below the AMI patients.9

Correlation analysis between the next-generation TnI and high sensitive TnI levels was calculated by Spearman rho coefficient correlation (ρ) and the result was 0.826 (p<0.01). This meant there was a strong positive correlation between next-generation TnI g and high sensitive TnI levels. The result was similar with the study of Peacock et al13 that revealed that the Spearman Rho coefficient correlation between the next-generation TnI and high sensitive TnI was 0.85.13 The correlation values were produced by analyzing the quantitative data TnI level that can be detected in each appliances. Some of the results outside the range of the detection of the appliance could not be analyzed and could give influence on the computing correlation coefficient. The amount of detection of the appliance gave limitations in data usage levels of the TnI. The use of the data level may be more useful for monitoring travel diseases with a serial examination compared with a single examination. The limitations of this research were difficulties to determine the onset of chest pain. The value of the correlation is

### Table 3. TnI ng and TnI hs data result in distribution based on diagnosis

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>ngTnI (Triage)</th>
<th></th>
<th>hsTnI (PathFast)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+*</td>
<td>-</td>
<td>Total</td>
<td>+*</td>
</tr>
<tr>
<td>Non-AMI</td>
<td>22</td>
<td>28</td>
<td>50</td>
<td>18</td>
</tr>
<tr>
<td>AMI</td>
<td>32</td>
<td>0</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>Total</td>
<td>54</td>
<td>28</td>
<td>82</td>
<td>50</td>
</tr>
</tbody>
</table>

* Positive defined as TnI ≥0.02 ng/mL for Triage and PathFast

Abbreviation: AMI, Acute Myocardial Infarction; ng TnI, Troponin next-generation; hs TnI, Troponin high sensitive
produced by analyzing the quantitative data in the form of TnI level that could be detected in each of the appliances. Some of the results outside the range of the detection by the appliance could not be analyzed and could give the influence on the computing correlation coefficient. Table 5 displayed the amount of data quantitatively analyzed statistically to obtain a correlation coefficient.

The concordance value between ngTnI and hsTnI in angina pectoris patients was 0.738 (p<0.01) showing that the ngTnI, a contemporary troponin I Point of Care (POC), was statistical equivalent with the high sensitive Troponin I. POCT is known easy to be used at bedside patients with small and portable instruments. The benefits can be felt by the angina patients especially in ED and ICU where the decision of diagnosing ACS can be made rapidly to reduce the complication and decrease the number of accidental deaths due to delays in the management of patients.14 The other method using Mitsubishi Pathfast, a high sensitive troponin I assay, can be used as confirmatory tools of the contemporary method in the case of a very low troponin I level in patient with angina pectoris. As shown in Table 1, the Coefficient Variation of hsTnI using Mitsubishi Pathfast is less than ngTnI using Alere Triage so the hsTnI method has a better precision than the ngTnI. In the case of the angina pectoris patients with an early attack so that the level of TnI still low, or patients in observation of TnI level serially, the hsTnI is more recommended to be used. Some other studies mentioned that POCT will reduce the clinical decision-making time between 1-2 hours after admission to the hospital.15,16

### Table 5. Distribution of troponin I level in the detectable level range

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>ngTnI (Triage)* n=63</th>
<th>hsTnI (PathFast)** n=80</th>
<th>Total subject n=82</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMI</td>
<td>6</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>STEMI</td>
<td>15</td>
<td>19</td>
<td>20</td>
</tr>
<tr>
<td>Non-AMI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UA</td>
<td>3</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Non ACS</td>
<td>39</td>
<td>46</td>
<td>46</td>
</tr>
</tbody>
</table>

* Detection range ngTnI : 0.01-10 ng/mL
** Detection range hsTnI: 0.01-50 ng/mL


### CONCLUSION AND SUGGESTION

This study concluded that there was a diagnostic concordance between ngTnI and hsTnI in angina pectoris patients. Both TnI assays showed a good value for helping to establish the diagnosis of ACS patients. Further research is needed for analyzing the prognostic value of TnI.

### REFERENCES


